UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study

Journal of inherited metabolic disease, 2014-11, Vol.37 (6), p.979-990

2014

Volltextzugriff (PDF)

Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients

Breast cancer research and treatment, 2016-07, Vol.158 (1), p.59-65

2016

Volltextzugriff (PDF)

Abstract OT1-1-14: A phase 2, 2-stage, 2-cohort study of the oral PARP inhibitor BMN 673 in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO study)

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.OT1-1-14-OT1-1-14

2015

Volltextzugriff (PDF)

A phase 2 study (2-stage, 2-cohort) of the oral PARP inhibitor talazoparib (BMN 673) in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.TPS1108-TPS1108

2015

Volltextzugriff (PDF)

A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.TPS1107-TPS1107

2015

Volltextzugriff (PDF)

Abstract OT1-1-12: A phase 3, open-label, randomized, parallel, 2-arm multi-center study of the oral PARP inhibitor BMN 673 versus physician's choice in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA study)

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.OT1-1-12-OT1-1-12

2015

Volltextzugriff (PDF)

Induction of Human Leukocyte Apoptosis and Phenotypic Alterations by LPS Infusion into Volunteers: 452

Shock (Augusta, Ga.), 1997-03, Vol.7 (Supplement), p.114

1997

Volltextzugriff (PDF)

Induction of Human Leukocyte Apoptosis and Phenotypic Alterations by LPS Infusion into Volunteers: 452

Shock (Augusta, Ga.), 1997-03, Vol.7 Suppl, p.114-114

1997

Volltextzugriff (PDF)

Immunodepressive Effects of LPS on Monocyte CD14in Vivo

The Journal of surgical research, 1997-04, Vol.69 (1), p.7-10

1997

Volltextzugriff (PDF)

Immunodepressive effects of LPS on monocyte CD14 in vivo

The Journal of surgical research, 1997-04, Vol.69 (1), p.7-10

1997

Volltextzugriff (PDF)

Embedded model palliative care (PC) at a community oncology practice in central Nebraska

Journal of clinical oncology, 2019-11, Vol.37 (31_suppl), p.64-64

2019

Volltextzugriff (PDF)

Establishing a General Medical Outpatient Clinic for Cancer Survivors in a Public City Hospital Setting

Journal of general internal medicine : JGIM, 2009-11, Vol.24 (Suppl 2), p.S451-455

2009

Volltextzugriff (PDF)

Establishing a General Medical Outpatient Clinic for Cancer Survivors in a Public City Hospital Setting: Cancer Survivorship Care for the General Internist

Journal of general internal medicine : JGIM, 2009, Vol.24

2009

Volltextzugriff (PDF)

OUTCOMES OF TREADMILL TESTING THE POST CORONARY INTERVENTION PATIENT. 10: 45 AM

Journal of cardiopulmonary rehabilitation, 1998-09, Vol.18 (5), p.346

1998

Volltextzugriff (PDF)

1 – 14 von 14

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(13)
Mit Volltextzugriff
(13)

Publikationsform

Artikel
(14)

Sprache

Englisch
(14)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study

Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients

Abstract OT1-1-14: A phase 2, 2-stage, 2-cohort study of the oral PARP inhibitor BMN 673 in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO study)

A phase 2 study (2-stage, 2-cohort) of the oral PARP inhibitor talazoparib (BMN 673) in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO)

A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA)

Abstract OT1-1-12: A phase 3, open-label, randomized, parallel, 2-arm multi-center study of the oral PARP inhibitor BMN 673 versus physician's choice in germline BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA study)

Induction of Human Leukocyte Apoptosis and Phenotypic Alterations by LPS Infusion into Volunteers: 452

Induction of Human Leukocyte Apoptosis and Phenotypic Alterations by LPS Infusion into Volunteers: 452

Immunodepressive Effects of LPS on Monocyte CD14in Vivo

Immunodepressive effects of LPS on monocyte CD14 in vivo

Embedded model palliative care (PC) at a community oncology practice in central Nebraska

Establishing a General Medical Outpatient Clinic for Cancer Survivors in a Public City Hospital Setting

Establishing a General Medical Outpatient Clinic for Cancer Survivors in a Public City Hospital Setting: Cancer Survivorship Care for the General Internist

OUTCOMES OF TREADMILL TESTING THE POST CORONARY INTERVENTION PATIENT. 10: 45 AM

Suchergebnisse filtern